Godavari Biorefineries Limited · NSE:GODAVARIB
Godavari Biorefineries — Q4 FY25 Earnings Presentation
21 slides from Godavari Biorefineries's earnings presentation, May 25, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
Dated: May 25, 2025 The Manager The Manager Listing Department Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Tower, Bandra Kurla Complex, Bandra (E), Dalal Street Mumbai – 400 051 Mumbai-400001 Script Symbol: GODAVARIB Script
Slide 2: Godavari Biorefineries Limited Investor Presentation Q4 & FY25
Godavari Biorefineries Limited Investor Presentation| Q4 & FY25
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Godavari Biorefineries Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for an
Slide 4: Q4 & FY25 Performance
Godavari ‘Biorefineries Ltd Q4 & FY25 Performance GROUP
Slide 5: Industry Updates
Industry Updates The global chemicals industry is seeing renewed momentum as companies accelerate the shift from fossil-based to bio-based chemicals. Bio-based Chemicals Gain Global players are actively collaborating to co-develop sustainable chemical solutions as part of the ongoing transition to b
Slide 6: Business Updates
Business Updates Accelerating Growth with Operational Excellence and Strategic Investments RECORD BREAKING CRUSHING STRENGTHENING CAPABILITIES ❑ The Sameerwadi unit achieved a record-high crushing of 24.65 lakh ❑ Our 200 KLPD fungible Grain/Maize distillery is progressing as planned, tons of sugarca
Slide 7: Q4 FY25 Performance Highlights
Q4 FY25 Performance Highlights (Consolidated) Revenue from Operations EBITDA PAT# Rs. 121.7 Cr Rs. 96.4 Cr Rs. 579.5 Cr Margin 21.0% Margin 16.6% Q4 FY25 Revenue-Mix * Q4 FY25 Geographical Split Finance Costs 11% -33% 33% 42% 19.5 13.1 24% 89% Q4 FY24 Q4 FY25 ₹240 crore term debt repaid through IPO
Slide 8: FY25 Performance Highlights
FY25 Performance Highlights (Consolidated) Revenue from Operations EBITDA PAT# Rs. 120.3 Cr Rs. 1.1 Cr Rs. 1,870.3 Cr Margin 6.4% Margin 0.1% FY25 Revenue-Mix * FY25 Geographical Split 10% 31% 39% 29% 90% Sugar & Co-Generation^ Bio based Chemicals Distillery Domestic Exports ^ contribution represent
Slide 9: Segmental Highlights-Bio-based Chemicals
Segmental Highlights-Bio-based Chemicals Revenue (Rs. Cr) Q4 FY25 Q4 FY24 YoY Growth FY25 FY24 YoY Growth 139 129 8% 542 506 7% Accelerating Growth Through Specialty Chemicals Revenue Break-up EBITDA +40% >2X 33% 42% 46% 47% 14 38 67% 58% 10 54% 53% 17 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 FY24
Slide 10: Segmental Highlights- Ethanol
Segmental Highlights- Ethanol Ethanol Units Q4 FY25 Q4 FY24 FY25 FY24 Production Volume KL 45,042 34,670 84,038 95,168 Sales Volume KL 35,333 26,844 85,204 84,058 B-Heavy Molasses Stock MT 1,09,244 0 1,09,244 0 C-Heavy Molasses Stock MT 0 44,893 0 44,893 Breakdown of Ethanol Production by Feedstock
Slide 11: Segmental Highlights- Sugar
Segmental Highlights- Sugar (In MT) Production Volume Sales Volume Inventory -18.2% -19.9% -38.3% 1,09,411 72,977 1,31,611 89,545 1,05,443 44,999 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY24 Q4FY25 -21.4% +23.5% -19.9% 1,87,659 1,72,459 1,31,611 1,47,433 1,39,606 1,05,443 FY24 FY25 FY24 FY25 Q4FY24 Q4FY25 10
Slide 12: Cancer Molecule Research Update
Cancer Molecule Research Update Drug Discovery for Triple-Negative Breast Cancer Approval obtained from Central Drugs Standard Control Organisation for clinical trials of a proposed drug on patients with advanced solid tumours. Molecule for safety trials currently being conducted, with completion ex
Slide 13: Consolidated Profit & Loss Statement – Q4 & FY25
Consolidated Profit & Loss Statement – Q4 & FY25 Particulars (in INR Cr) Q4 FY25 Q4 FY24 Y-o-Y Q3 FY25 Q-o-Q FY25 FY24 Revenue from Operations 579.5 615.2 -5.8% 447.3 29.6% 1,870.3 1,686.7 Other Income 9.3 10.5 3.6 16.7 14.4 Total Revenue 588.8 625.7 -5.9% 450.8 30.6% 1,886.9 1,701.1 Cost of Materia
Slide 14: Consolidated Balance Sheet – FY25
Consolidated Balance Sheet – FY25 Particulars (in INR Cr) Mar 25 Mar 24 Particulars (in INR Cr) Mar 25 Mar 24 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY 861.3 848.6 (i) Equity share capital 51.2 41.9 (i) Property, plant and equipment (ii) Other equity 730.8 458.7 (ii) Right to Use Asset
Slide 15: Consolidated Cash Flow Statement – FY25
Consolidated Cash Flow Statement – FY25 Particulars (in INR Cr) Mar 25 Mar 24 Cash Flow from Operating Activities Profit before Tax (1.5) 12.4 Adjustment for Non-Operating Items 114.3 123.3 Operating Profit before Working Capital Changes 112.7 135.8 Changes in Working Capital (106.4) 51.0 Cash Gener
Slide 16: Company Overview
Godavari Biorefineries Ltd \ Company Overview GROUP
Slide 17: Integrated Bio-refinery across value chain
Integrated Bio-refinery across value chain: Sugar, Ethanol, Bio-Chemicals, Power & Others… Planned Products GRAIN BASED ETHANOL SPECIALTY CHEMICALS Current Products BHUMILABH FARM INPUTS (BIO-FERTILAZERS) SUGARCANE WAX BIOGAS PRESSMUD SUGARCANE BEVERAGE SUGAR FARM MOLASSES JUICE BAGASSE ELECTRICITY
Slide 18: Focus on Improving Sugarcane Valorisation
….with Focus on Improving Sugarcane Valorisation Widest One of the top fifteen Large network of farmers Portfolio of bio-based products in India1 sugar complexes in India in terms of Crushing Capacity KARNATAKA MAHARASHTRA SAMEERWADI MANUFACTURING FACILITY SAKARWADI MANUFACTURING FACILITY Ethanol Bi
Slide 19: Key Growth Drivers
Key Growth Drivers Global - Transition to Green Chemistry India- Green Energy Transition Bio-Based Chemicals Ethanol Debottleneck Bio-Based Specialty Chemicals Diversify Feedstock by adding Grain/Maize bolt-on Capacity License Bio-Butanol Capacity for India Increase Capacity Utilization Increase pro
Slide 20: Board of Directors
Board of Directors Promoter has played a significant role in the development and growth of the company... Shri Samir Shantilal Somaiya (Chairman & Managing Director) • Conferred with the ‘ Knight of the Order of the Star of Italy’ • Conferred with ‘Lala Shriram National Award for Leadership in the C
Slide 21: Thank You
Thank You Godavari Biorefineries Ltd CIN: L67120MH1956PLC009707 Name – Mr. Ashish Sinha Title – AGM- IR & Finance investorrelations@somaiya.com Email – investorrelations@somaiya.com Ms. Prachi Ambre Mr. Irfan Raeen +91 83559 85370 Prachi.ambre@in.mpms.mufg.com +91 97737 78669 irfan.raeen@in.mpms.muf
Godavari Biorefineries — Q4 FY25 Earnings Presentation on 6ix